High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer by unknown
RESEARCH ARTICLE Open Access
High sensitivity isoelectric focusing to
establish a signaling biomarker for the
diagnosis of human colorectal cancer
Narendra Padhan1, Torbjörn E. M. Nordling1,2,4, Magnus Sundström1, Peter Åkerud3, Helgi Birgisson3,
Peter Nygren1, Sven Nelander1 and Lena Claesson-Welsh1*
Abstract
Background: The progression of colorectal cancer (CRC) involves recurrent amplifications/mutations in the
epidermal growth factor receptor (EGFR) and downstream signal transducers of the Ras pathway, KRAS and BRAF.
Whether genetic events predicted to result in increased and constitutive signaling indeed lead to enhanced
biological activity is often unclear and, due to technical challenges, unexplored. Here, we investigated proliferative
signaling in CRC using a highly sensitive method for protein detection. The aim of the study was to determine
whether multiple changes in proliferative signaling in CRC could be combined and exploited as a “complex
biomarker” for diagnostic purposes.
Methods: We used robotized capillary isoelectric focusing as well as conventional immunoblotting for the
comprehensive analysis of epidermal growth factor receptor signaling pathways converging on extracellular
regulated kinase 1/2 (ERK1/2), AKT, phospholipase Cγ1 (PLCγ1) and c-SRC in normal mucosa compared with CRC
stage II and IV. Computational analyses were used to test different activity patterns for the analyzed signal
transducers.
Results: Signaling pathways implicated in cell proliferation were differently dysregulated in CRC and, unexpectedly,
several were downregulated in disease. Thus, levels of activated ERK1 (pERK1), but not pERK2, decreased in stage II
and IV while total ERK1/2 expression remained unaffected. In addition, c-SRC expression was lower in CRC
compared with normal tissues and phosphorylation on the activating residue Y418 was not detected. In contrast,
PLCγ1 and AKT expression levels were elevated in disease. Immunoblotting of the different signal transducers, run
in parallel to capillary isoelectric focusing, showed higher variability and lower sensitivity and resolution.
Computational analyses showed that, while individual signaling changes lacked predictive power, using the
combination of changes in three signaling components to create a “complex biomarker” allowed with very high
accuracy, the correct diagnosis of tissues as either normal or cancerous.
Conclusions: We present techniques that allow rapid and sensitive determination of cancer signaling that can be
used to differentiate colorectal cancer from normal tissue.
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Background
Although the prognosis of patients with colorectal
cancer (CRC) is steadily improving, the disease re-
mains the second most common cause of cancer-
related deaths in Europe [1]. The treatment of CRC
is dependent on the disease stage and the location of
the tumor. Conventional treatment includes surgery,
radiation and chemotherapy (5-fluorouracil, irinotecan
and/or oxaliplatin) [2], often combined with bevacizumab
(a neutralizing antibody against vascular endothelial
growth factor; VEGF) or cetuximab/panitumumab (neu-
tralizing antibodies against epidermal growth factor recep-
tor; EGFR), depending on disease stage and patient-related
factors [3]. During the course of CRC, mutations accumu-
late in genes controlling cell survival and proliferation.
Several of the genes afflicted in CRC belong to the
RAS pathway [4]. The RAS pathway involves at least 4
key protein families (RAS, RAF, mitogen-activated pro-
tein kinase kinase (MEK) and extracellular regulated
kinase (ERK)) that are activated in a consecutive manner,
creating a signaling cascade that eventually results in
gene regulation. Approximately 50 % of metastatic CRCs
have activating mutations in the KRAS or NRAS genes
[5–7]. Patients with RAS mutations do not respond
favorably to treatment with neutralizing anti-EGFR anti-
bodies [8]. BRAF is the best characterized of three
closely related RAF proteins [9]. The BRAF gene har-
bors an activating mutation (V600E) in 5–12 % of all
CRC [10]. Tumors may have mutations either in KRAS
or BRAF though, as a rule, not in both [11]. Activation
of certain protein kinase C (PKC) isoforms, such as
PKCɛ, by phospholipase Cγ1 (PLCγ1), promotes RAF
activation [12]. BRAF in turn activates the dual tyro-
sine and serine/threonine kinase MEK, which is mu-
tated only very rarely in CRC [13]. The serine/
threonine kinases ERK1/2, downstream of MEK, are
also not mutated in CRC [13].
Cell proliferation is regulated also by the cytoplasmic
tyrosine kinase c-SRC, which is activated when phos-
phorylated on tyrosine residue (Y) 418 in the kinase do-
main and which is inhibited when phosphorylated on
the C-terminal Y527 [14]. c-SRC expression is reported
to be 5–8 fold higher in premalignant colorectal polyps
than in normal mucosa and a correlation between ele-
vated c-SRC levels and CRC progression/metastatic po-
tential has been suggested [15–17]. c-SRC kinase
inhibitors are being developed for therapeutic purposes
[18, 19]. Resistance to BRAF inhibition in melanoma
can be overcome by inhibiting c-SRC activity [20], indi-
cating a convergence of the pathways.
Cell survival is regulated by the phosphoinositide 3-
kinase (PI3K)/AKT pathway which, via mammalian
target of rapamycin complex 1 (mTORC1), eventually
results in activation of p70S6 kinase and gene induction
[21]. The serine/threonine kinase AKT is activated by
phosphorylation of threonine (T) 308 located in the kinase
domain and serine (S) 473 in the C-terminal end, by phos-
phatidylinositol-dependent kinase 1 (PDK1) and
mTORC2, respectively. The PI3K/AKT pathway is
negatively regulated by the lipid phosphatase, phos-
phatase and tensin homolog (PTEN) [22], which has
been identified as a tumor suppressor [23]. About 15
% of all CRCs have activating or suppressing muta-
tions in the PI3KCA gene, encoding the p110α cata-
lytic subunit of PI3K, as well as the PTEN gene [24].
Moreover, in wild type (non-mutated) KRAS gene
tumors, the presence of PI3K and PTEN mutations
indicates a poor prognosis [25].
To identify mutations in cancer is part of an effort to
individualize each patient’s treatment. However, muta-
tions may not result in changes in protein expression
levels and/or activity, and the mutation status of a
particular cancer may fail to convey information about
additional events occurring during progression of the
disease, which may override a particular mutation, e.g.
compensatory upregulation of other proteins and path-
ways [26]. There is no doubt that the EGFR/RAS path-
way and downstream ERK1/ERK2 activities are essential
in CRC etiology and disease progression [27]. However,
predicting RAS pathway activity is particularly complex
as there are several different upstream and parallel acti-
vators on different levels and many alternative feedback
loops [26]. Apart from the regulation of RAS activity
through GTPase regulatory proteins (GAPs and GEFs),
downstream signaling in the RAS pathway can be
induced or modulated through activities in several other
pathways, including the PLCγ/PKC, PI3K/AKT and c-
SRC pathways. Another complicating aspect of RAS
signaling in CRC is chromosomal fragility. 85 % of
sporadic CRC cases display chromosomal instability,
chromosome amplification and translocation leading to
aneuploidy (see [28] and refs therein), whereas the
remaining 15 % of patients have high-frequency
microsatellite instability phenotypes i.e. frameshift
mutations and base pair substitutions [29]. The
chromosomal instability of CRC clearly influences the
biological consequence of the mutations. Thus, taken
together, the presence of a mutation in a signaling
protein does not necessarily predict activity in the cor-
responding signaling pathway.
Due to the existing challenges in CRC therapy, the
development of rapid and sensitive screens to measure
the biological activity of key signal transducers, which
could serve as drug targets or as predictive or prognostic
biomarkers, is warranted. Previously, the CRC proteome
has been investigated using mass spectrometry to iden-
tify up- and downregulation of proteins, using mostly
cell lines but also, to some extent, patient samples [30].
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However, this is the first study to comprehensively
address the proliferative signaling proteome in CRC
tissues. For this purpose, we have developed protocols
for highly sensitive, robotized isoelectric focusing, to
show that signaling in the RAS pathway is dysregulated
in human CRC primary tumors compared with normal
mucosa. Moreover, by computational and geometric
assessment of the signal transduction patterns in the dif-
ferent tissues examined (normal, stage II and stage IV
CRC), we show that combinations of patterns from
several pathways could serve as biomarkers and be
exploited for the classification of tissues as normal or
cancerous. We suggest that further refinement of com-
plex signatures can be exploited for prognostic purposes.
Methods
Tumor biopsy collection
The colorectal tumor sampling and characterization of
the anonymous samples was approved by the Uppsala
Regional Ethical Review Board (no 2007/005 and 2000/
001). Prior to the operation the patient was asked by the
responsible surgeon to donate tumor tissue and blood
samples for future molecular studies. Patients agreeing
to participate were given written study information and
signed an informed consent form. When the surgical
specimen (colon) was removed from the patient, it was
immediately transported on ice to the histopathological
department and a clinical pathologist cut a 5x5x5 mm
biopsy from the periphery of the primary tumor and a
10x10 mm normal mucosa more than 5 cm from the
primary tumor. The biopsies were immediately placed,
without addition of medium, in test tubes, which were
stored at -80 °C until analyses were made. Thirty-three
colon cancer samples were selected from a set of fro-
zen tumor biopsies collected from patients operated
upon for colorectal cancer at the hospitals in Karlstad
or Västerås, Sweden. Seventeen of the 33 patients had
stage II colon cancer and 16 had stage IV colon cancer.
Samples of normal mucosa from 18 patients were
available for analyses.
Cell culture and VEGF treatment
Human umbilical vein endothelial cells (HUVECs;
ATCC; Manassas, VA) were cultured on gelatin-coated
10 cm tissue culture petri dishes in endothelial cell
basal medium MV2 (EBM-2, C-22221; PromoCell,
Heidelberg, Germany) with supplemental pack C-
39221, containing 5 % FCS, epidermal growth factor (5
ng/ml), VEGF (0.5 ng/ml), basic FGF (10 ng/ml),
Insulin-like Growth Factor (Long R3 IGF, 20 ng/ml),
hydrocortisone (0.2 μg/ml), and ascorbic acid (1 μg/
ml). HUVECs at passages 3–6 were used. For experi-
mental purposes, ECs were serum-starved overnight
and plated in EBM-2 medium, 1 % FCS without growth
factor supplement and treated with/without VEGF (50 ng/
ml, Preprotech, Rocky Hill, NJ) for 7.5 min or 15 min.
The cells were lysed in a commercial RIPA buffer contain-
ing protease inhibitor mix (# 040-482, ProteinSimple,
Santa Clara, CA) and phosphatase inhibitors (# 040-510,
ProteinSimple). The lysates were clarified by centrifuga-
tion and protein concentrations were determined by using
BCA Protein Assay Kit (Pierce ThermoFisher Scientific,
Rockford, IL, USA).
Isoelectric focusing
CRC tissue samples were lysed in RIPA buffer containing
phosphatase and protease inhibitors (ProteinSimple). The
tissue lysates were clarified by centrifugation and protein
concentration was measured by using BCA Protein
Assay Kit (Pierce/ThermoFisher Scientific). Samples
were run in triplicates. Lysates were mixed with
ampholyte premix (# 040-972, G2 pH 5-8 or # 040-968,
G2 pH 3-10) and fluorescent isoelectoric point (pI)
standards (# 040-646, pI Standard Ladder 3) before
being loaded into the NanoPro 1000 system (Protein-
Simple) for analysis. Isoelectric focusing was performed
in capillaries filled with a mixture of cell lysate (0.05–0.2
mg/ml protein), fluorescently labeled pI standards, and
ampholytes. The separated proteins were cross-linked
onto the capillary wall using UV light, and immobilization
was followed by immunoprobing with anti-ERK1/2
(1:50, # 9102), anti-pERK1/2 (# 4377, 1:50) and anti-
PLCγ1 (# 2822, 1:50) antibodies from Cell Signaling
Technology (Danvers, MA); anti-AKT (# sc-8312, 1:20),
p70S6 kinase (# sc-8418, 1:50), and MEK 1/2 (# sc-436,
1:50) antibodies from Santa Cruz Biotechnology Inc.
(Dallas, Texas); anti c-SRC (# ab47405, 1:50) antibodies
from Abcam; and anti-EGFR (# 05-484, 1:50) antibodies
from Merck Millipore (Darmstadt, Germany). Analysis
of HSP 70 (# NB600-571, 1:500), Novus Biologicals
(Littleton, CO) was run in parallel for normalization.
HRP-conjugated secondary antibodies were used, either
from ProteinSimple (Goat anti rabbit-HRP IgG, # 041-
081 and Goat anti mouse-HRP IgG, # 040-655 both at
1:100) or from Jackson ImmunoResearch (West Grove,
PA) (Donkey anti-Rabbit IgG, # 711-035-152 and Don-
key anti-Mouse-HRP IgG # 711-035-150, both at
1:300), to detect the signal. In some cases, signal ampli-
fication steps were employed by using an amplified
rabbit (# 041-126, 1:100) or amplified mouse (# 041-
127, 1:100) secondary antibody detection kit (Protein-
Simple). The signal was visualized by enhanced chemi-
luminescence (ECL) and captured by a charge-coupled
device (CCD) camera. The digital image was analyzed
and peak area quantified with Compass software (Pro-
teinSimple). The peak area of the protein of interest
was normalized to the area of heat shock protein 70
(HSP70) in the sample, analyzed in parallel.
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Lambda phosphatase digestion
Some samples were enzymatically dephosphorylated by
incubating 8–15 μg of cell lysate with 50 units of
lambda phosphatase (# 14-405; Upstate Biotechnology,
Charlottesville, VA), for 5-30 min at 30 °C, where incuba-
tion time was titrated independently for each signaling
component. Digested samples were subjected to immuno-
blotting or isoelectric focusing as described above.
Mutation analysis
KRAS pyro-sequencing mutational analysis was per-
formed according to the manufacturer’s protocol for the
PyroMark™ Q24 KRAS Pyro kit (QIAGEN GmbH, Hilden,
Germany) and the use of PCR primers previously de-
scribed for KRAS codon 12/13 [31], codon 61 [32], and
for BRAF codon 600 [31]. Ten ng genomic DNA from the
patients tumor tissue was used for each PCR reaction.
Twenty μl PCR product was then subjected to Pyro-
sequencing analysis using Streptavidin Sepharose High
Performance beads (GE Healthcare, Chicago IL), Pyro-
Mark Gold Q96 reagents, PyroMark Q24 2.0.6 soft-
ware, and a Q24 instrument (QIAGEN). Sequencing
primer for KRAS codon 12/13 was 5′-AACTTGTGG
TAGTTGGAGCT-3′, for codon 61 5′-TCTTGGA
TATTCTCGACACAGCAG-3′, and for BRAF codon
600 5′-TGATTTTGGTCTAGCTACA-3′. Due to sub-
optimal DNA quality, two samples were not suitable
for mutation analysis (denoted “unclear” in the figures).
Immunoblotting
Ten μg of CRC tissue- or cell lysate was mixed with
lithium dodecylsulfate sample buffer and Sample Redu-
cing Agent and heated at 70 °C for 10 min. The pro-
teins were resolved on NuPAGE Novex 4–12 % Bis-Tris
SDS PAGE Gel (Life Technologies, Carldsbad, CA) and
transferred onto PVDF membranes (Immobilon-P
IPVH00010; Merck Millipore). The membranes were
blocked by using 5 % (w/v) nonfat dry milk/BSA in TBS
with 0.1 % Tween 20 for 1 h at RT, which was followed
by incubation over night at 4 °C with primary antibodies
pERK 1/2 (# 4377, 1:1000), ERK1/2 (# 9102, 1:1000), SRC
pY416 (# 2101, 1:1000), SRC pY527 (# 2105, 1:1000), pAKT
(# 4060, 1:1000), AKT (# 9272, 1:1000), PLCγ1 (# 2822,
1:1000), all from Cell Signaling Technology. SRC (#
ab47405, 1:1000) and β2M (# ab75853, 1:2000) were from
Abcam. EGFR (# 05-484, 1:2000) and GAPDH (# MAB374,
1:1500) from Merck Millipore, α-Tubulin (# T9026, 1:1000)
from Sigma-Aldrich (Saint Louis, MI), p70S6 kinase (# sc-
8418, 1:2000) from Santa Cruz Biotechnologies Inc, HSP 70
(# NB600-571, 1:1000) from Novus Biologicals. Proteins of
interest were detected with HRP-conjugated donkey anti-
rabbit IgG antibody (# NA934, 1: 15000) or sheep anti-
mouse IgG antibody (# NA931, 1: 15000), visualized with
using ECL Prime (# RPN2232) and exposed to either the
Hyperfilm ECL (# 28906837) all from GE Healthcare.
Signals were visualized using the ChemiDoc™ MP Imaging
System (Bio-Rad Laboratories, Herkules, CA) according to
the provided protocol.
All antibodies used for the isoelectric focusing were
tested for specificity by immunoblotting of HUVEC
lysates (for AKT, p70S6 kinase, PLCγ1, c-SRC, SRC
pY527, ERK1/2, HSP 70 and MEK 1/2) and lysates
from A431 cells (#12-302, Merck Millipore) for EGFR
(see Additional file 1: Figure S1). Certain antibodies,
such as the anti-c-Src antibodies were also validated
elsewhere for example at the MD Anderson Functional





The Mann-Whitney U test was used to calculate two-
tailed p-values of the null hypothesis that the popula-
tions of the two compared features (proteins) are the
same. p < 0.05 was considered statistically significant. *,
p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.
The Mann-Whitney test is a conservative, non-
parametric test that was chosen to preclude false detec-
tions arising from assumptions of data distribution.
Identification of tissue signatures
For assessment of data sets and the creation and evalu-
ation of convex hulls for classification of the tissue sam-
ples based on signatures, see Additional file 1: Figure S3,
Characteristics of the data set and errors.
Results
Regulation of EGFR expression and activity in CRC
Whereas activating mutations in the EGFR gene are
rare in CRC, protein levels may be increased as a result
of gene amplification or through other mechanisms
e.g. involving increased translation or decreased in-
ternalization and degradation. We used isoelectric fo-
cusing for sensitive and high-resolution detection of
EGFR expression in tissues, comparing normal mucosa
(18 samples) with CRC samples (17 samples from stage
II and 16 samples from stage IV). The mutation status
of the CRC samples was determined for KRAS and
BRAF. Tissues were lysed and, in a robotized proced-
ure, proteins were immobilized to the wall of thin
capillaries using UV exposure, followed by incubation
with primary and secondary antibodies and ECL-
detection, as outlined schematically in Fig. 1a. Tissue
lysates and antibodies were loaded at desired concen-
trations in 384-well plates placed under the capillary
holder in the instrument. As shown in Fig. 1b and c,
there was no significant difference in the expression
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levels of EGFR when comparing normal tissue with stage
II and IV CRC using isoelectric focusing, although the me-
dian was numerically lower in stage IV samples. The peaks
corresponding to antibody detection of EGFR were nor-
malized to those of HSP70 run in parallel. There was no
correlation between EGFR levels and the KRAS or BRAF
mutation status, in this analysis.
Regulation of AKT and p70S6K pathways in CRC
Signaling in the PI3K/AKT pathway results in down-
stream activation of mTOR and p70S6 kinase and
ultimately, cell survival and proliferation [33]. The level
of AKT expression and activity was first analyzed by
immunoblotting on normal mucosa and CRC samples
(Fig. 2a). The level of AKT pS473 was elevated in stage
II CRC, but the variability was considerable in this con-
ventional analysis. Isoelectric focusing followed by de-
tection of AKT resulted in a reproducible pattern with
several peaks, when probed with an antibody against
total AKT proteins, AKT1, AKT2 and AKT3 (Fig. 2b).
The pattern of AKT-peaks was reminiscent but not
identical to that described in previous reports where
isoelectric focusing was used to investigate the in vitro
regulation of the AKT pathway in cell lines from breast
cancer and acute myeloid leukemia [34, 35].
Phospho-specific AKT antibodies did not permit spe-
cific detection of protein species in the isoelectric fo-
cusing (data not shown). Through lambda phosphatase
digestion, however, several pAKT isoforms were identi-
fied (Fig. 2b; P1-4 and P6), possibly representing dis-
tinct AKT family members phosphorylated on different
residues. The optimal conditions for lambda phosphat-
ase digestion were determined by immunoblotting of
phosphatase-treated control (HUVEC) cell lysates,
which showed that the phosphatase treatment resulted
in phosphate stripping without digestion of protein
(Fig. 2c). Of note, the levels of pAKT and total AKT as
detected in the capillary isoelectric focusing were sig-
nificantly higher in the CRC tissues compared with
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Fig. 1 Sensitive isoelectric focusing of EGFR in normal mucosa and CRC. a. Schematic outline of the isoelectric focusing procedure. 400 nl of
protein lysates from cultured cells or tissues are passed through the capillaries, followed by probing with antibodies and detection using ECL,
resulting in an electropherogram. b. Representative electropherogram showing EGFR protein peaks. c. Plot of individual HSP70-normalized peak
areas from EGFR electropherograms on normal mucosa or CRC samples. Symbols in plots indicate the mutation status of CRC biopsies: Red; KRAS
mutated, green; BRAF mutated, blue; wild type (WT) with regard to KRAS and BRAF, black; unidentifiable (unclear) for KRAS and BRAF
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AKT did not change, however, indicating that the rela-
tive AKT phosphorylation level was not affected by the
disease (Fig. 2f ). The protein level of p70S6 kinase, a
serine/threonine kinase activated downstream of PI3K/
AKT, was similar in the cancer samples as compared to
normal mucosa (Fig. 2g-h).
Upregulation of PLCγ1 protein in CRC stage II and stage IV
PLCγ1 is known to activate the RAS pathway to pro-
mote cell proliferation via PKC. Conventional immuno-
blotting for PLCγ1 allowed detection of a very faint
band in the tissue lysates of normal samples while CRC
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Fig. 2 Detection of total AKT protein and phospho-protein by isoelectric focusing. Plots (d-f, h) show values after normalization to HSP70
levels analyzed in parallel in each sample. Symbols in plots: Red; KRAS mutated, green; BRAF mutated, blue; wild type (WT) with regard to
KRAS and BRAF, black; unclear for KRAS and BRAF. a. Immunoblotting of selected tissue samples with antibodies against pAKT (AKT pS473)
and total AKT protein. Blotting for β2 microglobulin (β2M) was used as a loading control. b. Representative electropherogram showing
phosphorylated and non-phosphorylated AKT peaks. Blue and green lines indicate electropherograms of samples digested (green) or not
(blue) with lambda phosphatase. Inset; electropherogram showing HSP70 run in parallel. c. Immunoblotting of HUVEC (±VEGF for 15 min)
cell lysate with antibodies against pAKT and total AKT protein. Blotting for tubulin was used as to monitor equal loading. Control; without
any incubation; Buffer; control lysate incubated with buffer, Phosphatase; lysate incubated with lambda phosphatase enzyme. d. Plot of
total AKT peak areas (P1–P8) in the different samples. e. Plot of pAKT peak areas (present before but not after lambda phosphatase
treatment; P1–P4 and P6). f. Plot of the ratio of pAKT/AKT peak areas. g. Representative electropherogram of p70S6 kinase expression.
h. Plot of p70S6 kinase expression normalized to HSP70
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protein. In CRC stage IV samples, the signal was slightly
lower (Fig. 3a). Capillary isoelectric focusing resulted in
two very closely migrating peaks (Fig. 3b) which were
both resistant to lambda phosphatase treatment. Anti-
bodies against phosphorylated PLCγ1 failed to yield a
signal in the isoelectric focusing (data not shown).
Quantification of the combined areas of the two peaks
showed a significant increase in PLCγ1 expression in
stage II and IV samples (Fig. 3c), in agreement with the
immunoblotting data. Moreover, the variability in
expression level was higher in the cancer samples than
in the normal tissue biopsies. Combined, these data indi-
cate that while total PLCγ1 was upregulated in CRC, there
was low or no accumulation of phosphorylated PLCγ1.
Decreased c-SRC phosphorylation in CRC
We also investigated the expression and activity of c-
SRC, as its activity results in the downstream induction
of several signaling pathways regulating cell prolifera-
tion. An antibody against total c-SRC detected several
species upon immunoblotting of normal and stage II
samples. In contrast, stage IV samples showed very faint
or no expression of c-SRC (Fig. 4a). Moreover, all sam-
ples lacked reactivity with antibodies against c-SRC
pY418, indicating low or no c-SRC activity in the colon
(Fig. 4a, upper panel). Control immunoblotting of
lysates from growth factor stimulated cells verified that
the anti c-SRC pY418 antibodies recognized the ex-
pected 60 kDa species (Fig. 4a, lower panel). Moreover,
immunoblotting with antibodies against the inactivating
c-SRC pY527 residue revealed prominent bands in both
the control cell lysate and in selected CRC samples
(Fig. 4a, lower panel). Thus, conventional immunoblot-
ting for total c-SRC and the phosphorylated variants
showed a complex and variable pattern.
Isoelectric focusing detected six major c-SRC species
(Fig. 4b); five peaks with a more acidic isoelectric point
disappeared with lambda phosphatase digestion and were
collected in one peak with a more basic pI of 6.5 (Fig. 4b).
Probing with the c-SRC pY527 antibodies showed that the
majority of the pSRC species in peaks (P)1-3,5 contained
phosphorylation at the inactivating Y527 (Fig. 4c). The vari-
ous pY527 antibody-reactive phosphospecies focusing at
different pI may correspond to c-SRC variants with differ-
ent posttranslational modifications such as serine/threonine
phosphorylation [36]. We can not exclude that certain mo-
lecular species may correspond to c-SRC related proteins,
containing highly similar epitopes. However, the normalized
peak areas for all peaks (Fig. 4d, denoted “SRC”) showed
that c-SRC expression was significantly lower in CRC stages
II and IV, compared with normal tissues. The area of the
combined “pSRC” peaks P1-P5 (Fig. 4e) was also lower in
the CRC samples. Moreover, the ratio of pSRC/SRC (Fig. 4f)
was lower in CRC than in normal mucosa, indicating that
the level of inactivating pY527 phosphorylation was
reduced in the cancer compared with normal tissues. There
was no apparent correlation between the decreased levels
of pSRC/SRC and KRAS/BRAF mutation status.
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Fig. 3 Detection of PLCγ1 total protein by isoelectric focusing. a. Immunoblotting of selected tissue samples with antibodies against PLCγ1.
Blotting for GAPDH and β2 microglobulin (β2M) were used as loading control. b. Representative electropherogram showing PLCγ1 total protein
peaks. Inset; electropherogram showing HSP70 run in parallel. c. Plot of PLCγ1 peak areas in samples from normal tissue, CRC stage II and IV
biopsies. Values were normalized to HSP70 levels. Symbols in plots: Red; KRAS mutated, green; BRAF mutated, blue; wild type (WT) with regard to
KRAS and BRAF, black; unclear for KRAS and BRAF
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Decreased level of pERK1, but not expression level, in CRC
Growth factors regulate cell proliferation in the RAS
pathway by modifying downstream phosphorylation of
the serine/threonine kinases ERK1, on T202/Y204, and
ERK2, on T185/Y187. Phosphorylated and nuclearly
translocated ERK1/2 catalyze phosphorylation and
thereby activation of a range of nuclear transcription
factors [37, 38]. Immunoblotting for pERK1/2 showed
variable expression in normal mucosa, high expression
in stage II and lower expression again in stage IV
CRC. The levels of pERK1/2 were variable over the
panel of immunoblotted samples (Fig. 5a). Isoelectric
focusing on the other hand resolved total ERK1/2 into
six major peaks representing both phosphorylated and
non-phosphorylated ERK isoforms (Fig. 5b). Using a
combination of antibodies reactive with both ERK1 and
ERK2, antibodies specifically recognizing only one of the
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Fig. 4 Detection of c-SRC total protein and phosphorylated forms by isoelectric focusing. Plots (d–f) show values after normalization to HSP70
levels. Symbols in plots: Red; KRAS mutated, green; BRAF mutated, blue; wild type (WT) with regard to KRAS and BRAF, black; unclear for KRAS and
BRAF. a. Immunoblotting of selected tissue samples with antibodies against c-SRC pY418, c-SRC pY527 and total SRC protein. For upper panel,
loading control β2M was same as Fig. 2a. GAPDH was used as a loading control for lower panel. Control; HUVEC cell lysate was used as a positive
control. b. Representative electropherogram showing c-SRC total protein and phosphoprotein peaks. Phosphorylated peaks (blue line) were
identified by virtue of their sensitivity to lambda phosphatase digestion (green line). Inset; electropherogram showing HSP70 run in parallel.
c. Representative electropherogram showing c-SRC pY527 peaks. d. Plot of combined c-SRC peak (P1–P6) areas in normal mucosa, stage II and
stage IV CRC. e. Plot of phosphorylated c-SRC peak (P1–P5) areas. f. Plot of the ratio pSRC/SRC
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identity of each peak could be mapped (Fig. 5b). Quantifica-
tion of the normalized peak areas showed no difference in
expression levels of ERK1 between normal mucosa and
cancer stage II and IV. However, accumulation of pERK1
decreased in the CRC samples compared to the normal
tissue resulting in a significantly decreased pERK1/ERK1
ratio (Fig. 5c). Although ERK2 levels increased in the CRC




































































































































































Normal Stage II Stage IV
K-Ras mutated B-Raf mutated WT Unclear
Fig. 5 Detection of ERK1/2 total protein and phosphorylated forms by isoelectric focusing. Plots (c–e) show values after normalization to HSP70
levels. Symbols in plots: Red; KRAS mutated, green; BRAF mutated, blue; wild type (WT) with regard to KRAS and BRAF, black; unclear for KRAS and
BRAF. a. Immunoblotting of selected tissue samples with antibodies against pERK1/2 and total ERK1/2 protein. Loading control β2M was same as
shown in Fig. 2a. b. Representative electropherogram showing ERK1/2 total protein peaks. c. Plot of individual peak areas from ERK1 (ppERK1+
pERK1 + ERK1) analyses of normal mucosa and CRC stage II and IV (top) and of pERK1 (ppERK1 + pERK1)/ERK1 peak areas (bottom) after
normalization for HSP70 run in parallel. d. Plot of normalized ERK2 (ppERK2 + ERK2) protein peaks (top) and pERK2 (ppERK2)/ERK2 (bottom).
e. Plot of normalized, combined ERK1/2 total protein peaks (top) and combined pERK1/2 over total ERK1/2 peaks (bottom)
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(Fig. 5d). The decrease in pERK1 levels dominated over the
increase in pERK2 levels, as a cross-reactive pERK1/2 anti-
body also showed lower phosphoprotein levels in the
cancer samples (Fig. 5e).
Computational selection of proteins to distinguish CRC
from normal tissue
Since individual pathways associated with epithelial cell
proliferation showed a very complex pattern in the CRC
tissues, we conducted a computational search for combi-
nations of proteins from several pathways that would
allow for the discrimination of normal tissue samples
from CRC. The overlap between the convex hulls of the
data points from normal tissue and CRC stage II or stage
IV was examined for every possible combination of up
to three features. In addition to the measured 23 differ-
ent variants (represented by individual peaks in the elec-
tropherograms shown in Figs. 1, 2, 3, 4 and 5) for EGFR,
AKT, p70S6K, PLCγ1, c-SRC, ERK1, ERK2, and MEK1/2
(see Additional file 1: Figure S2 for MEK1/2 analyses),
we also included 15 features constructed as the sum of
phosphorylated or non-phosphorylated forms of the
seven proteins and their ratios. For detailed description
on computational analyses and machine learning see
Additional file 1: Figure S3; Characteristics of the data
set and errors.
In mathematics, the convex hull of a set is the minimal
convex set that covers all points in the set. Applied in
this context, the convex hull represents the region in
protein space that encompasses all observations for
either one of the cancer stage or the normal tissue. As
shown by the minimal overlap of the convex hulls in
Fig. 6, the combination of total pERK1, SRC peak 6 and
p70S6K peak 3, separated normal tissue from CRC II
and CRC IV. In other words, these three patterns yield a
“signature” that was distinct for normal and cancer tis-
sue and measurement of these proteins was sufficient
for classification of a tissue sample as normal or CRC.
Only one CRC stage IV sample fell within the convex
hull of the normal tissues. The convex hulls of the two
CRC stages overlapped implying that the combination
used (pERK1, SRC peak 6 and p70S6K peak 3) was
not appropriate for classification of the disease stage.
Monte Carlo simulations revealed that the separation
of the non-cancer versus cancer sets was highly un-
likely to occur by chance (p-value <10-6; multiple hy-
pothesis corrected p-value <10-2). Thus, with this
strategy, a unique signature for normal tissue versus
cancer tissue was obtained.
Discussion
Substantial research efforts over the last decades have
resulted in increased understanding of CRC mutations
and molecular consequences; still, due to the complexity
of the tumor biology and the heterogeneity of the
cancer, CRC remains a fatal disease. Here, we show
that signaling pathways regulating cell survival and
proliferation were differently regulated in CRC tissues
compared to normal mucosa. Expression of ERK1 and
SRC appeared significantly suppressed in CRC tissues
compared with normal mucosa while expression of
AKT and PLCγ1 were upregulated. See Table 1 for a
summary of the pattern of proliferative CRC signaling
identified in this study.
Signaling was analyzed using capillary isoelectric
focusing, which we found to be superior to conventional
immunoblotting in sensitivity and resolution. After load-
ing of samples and antibodies, the processing was robot-
ized, resulting in highly reproducible and sensitive
detection. For example, ERK1/2 protein was detected in
2.5 ng of CRC lysate per capillary (corresponding to 6.25
μg/ml total lysate). Moreover, protein variants, phos-
phorylated at different residues, could be separated and
quantified independently. For ERK1/2 proteins, six of
the isoforms (pERK1, ppERK1, ERK1, pERK2, ppERK2,
ERK2) could be identified and quantified in relation to
the house keeping proteins analyzed in parallel. In com-
parison, conventional immunoblotting run on the same
samples required much more protein for each analysis.
It often failed to resolve protein phospho-variants and
reproducibility was low, in part due to problems with
Fig. 6 Convex hulls separating normal, CRC stage II and IV tissues.
Convex hulls of the sets of all data points of each tissue class
representing total pERK1 (ppERK1 + pERK1) peaks, SRC P6 and
p70S6K P3 allowed separation of normal tissues (green) from CRC
stage II (blue) and stage IV (red). Each dot represents a
computationally analyzed data point
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transfer of proteins to the filter. Ongoing efforts include
adapting the isoelectric focusing protocol for the detec-
tion of signal transducers in formalin-fixed, paraffin-
embedded samples to make the procedure applicable in
clinical routines.
Using the isoelectric focusing strategy, several im-
portant observations were made that can be related
to earlier reports on CRC signaling (see also summary
in Table 1):
I) AKT: In agreement with our findings on increased
AKT protein expression in the CRC tissues,
colorectal adenomas and carcinomas frequently
overexpress AKT [39] at an early stage in the
disease. Moreover, other components in the PI3K/
AKT pathway are affected in CRC. The most
common event is a loss of expression of, or
mutation in PTEN, which occurs in close to 50 %
of the premalignant lesions [40].
II) PLCγ1: Studies on a limited number of CRC
samples showed increased PLCγ1 protein levels
whereas other PLC family members, PLCβ1 and
PLCδ1, remained unaffected [41]. However,
whether the increased protein levels are
accompanied by increased phospholipase activity
in CRC remains unclear. Phosphorylation of
PLCγ1 is known to induce its catalytic activity
however, we failed to detect phosphorylated
PLCγ1 in the CRC samples studied here.
III) c-SRC is a key signal transducer whose activity may
initiate most, if not all, other pathways related to cell
proliferation [42], and the expression and activity of
c-SRC have been associated with CRC progression
[15, 16, 42]. However, in several studies, c-SRC
activity has been analyzed using an in vitro immune
complex kinase assay on cell lines, rather than on
clinical samples [43–45]. The lack of pY418
phosphorylated c-SRC and the decrease in
expression in disease shown here (Fig. 4), indicate
that c-SRC does not drive CRC tumor cell
proliferation. Also, pathways potentially induced
as a consequence of c-SRC activation in CRC,
such as the Scatter factor/c-Met pathway, may
not be crucial [46]. c-SRC kinase activity is regulated
by tyrosine phosphorylation/dephosphorylation. We
detected c-SRC pY527 in all samples, although the
amount decreased in disease. As there was no parallel
increase in c-SRC pY418, it appears that overall, there
is limited c-SRC activity in CRC. The decrease in
pY527 levels may depend on phosphatase activity with
c-SRC being dephosphorylated e.g. by the tyrosine
phosphatase PTPRO [47]. Apart from the well
characterized positive regulatory pY418 and negative
regulatory pY527, there are other phosphorylation
sites in c-SRC including pS17 and pY215 whose
functions have remained unclear [36]. The many
phospho-SRC peaks identified in the isoelectric
focusing indicate that, in CRC, c-SRC can become
modified at yet additional sites. However, as the
critical pY418 is lacking, it is questionable whether
c-SRC is a suitable target for CRC therapy. Another
complicating aspect of studying c-SRC’s role in cancer
biology is the high degree of structural relatedness
with other SRC family tyrosine kinases (SFKs), first
and foremost the ubiquitously expressed FYN and
YES. Thus, we cannot exclude that c-SRC, YES, and
FYN phosphoproteins may all have been detected by
the c-SRC reagents used here, due to the highly
conserved phosphorylation sites in all three members.
Overall, insight on the role of the different SFKs in
CRC is lacking.
IV)ERK1/2: Aberrant colon crypt foci, which are
believed to predict a malignant process, were
analyzed using a similar methodology to that applied
in this study, revealing elevated levels of both
pERK1 and pERK2 irrespective of KRAS and BRAF
mutation status [48]. ERK1 and ERK2 are highly
related structurally and are largely co-regulated and
indeed, in many aspects, redundant. However, ERK2,
but not ERK1, has been shown to contribute to
Table 1 Summary of changes in signaling components








EGFR + + + Similar levels in benign, CRC
II and IV.
pAKT/AKT + + + Total levels of pAKT and AKT
upregulated in CRC but pAKT/AKT
ratios were similar in the different
samples.
p70S6K + + + Similar levels in benign, CRC
II and IV.
PLCγ1 - +++ + + Low or no PLCγ1 expression in
benign samples and higher
levels in CRC. pPLCγ1 was
not detected in any samples.
SRC pY527/SRC +++ + + Low or no SRC pY418 in all
samples. Lower SRC pY527/SRC
ratios in CRC II and IV compared
to benign.
pERK1/ERK1 +++ + + Reduced pERK1/ERK1 ratio in CRC
II and IV compared to benign.
pERK2/ERK2 ++ ++ ++ Similar ratios benign, CRC
II and IV.
MEK1/2 + + + Similar levels in benign, CRC
II and IV.
+, ++ and +++ indicate different relative levels or ratios for a particular
signaling component when comparing normal, CRCII and CRCIV samples,
and should not be applied to compare levels/ratios between the different
signaling components
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RAS-induced oncogenic signaling [49], and yet,
ERK1 has been implicated in the negative regulation
of ERK2 [50]. Therefore, the reduced pERK1 levels
in CRC that we describe here may unleash ERK2
activity, resulting in increased oncogenic signaling in
primary tumors. Regulation of ERK1/2 signaling is
truly complex, with scaffold proteins, including
KSR1/2, IQGAP1, MP1, and β-Arrestin1/2,
participating in the regulation of the ERK1/2
MAP kinase cascade [26]. Furthermore, ERK1/2 are
dephosphorylated by several different phosphatases
[51] that may be differently expressed.
Several decades of ambitious basic and clinical research
have demonstrated the challenges in identifying reliable
biomarkers in cancer. Challenges include the complexity
of the primary tumor tissue consisting of, apart from the
tumor cells, a range of host-derived endothelial, fibroblast
and inflammatory cells; potential differences between the
primary tumor and metastasis; and the possibility that bi-
opsies may not be representative. In this study, the pro-
portion of tumor cells ranged from about 30–60 % in
most samples, based on the estimation of mutated DNA/
total DNA in the samples (data not shown). An important
conclusion from the current study is that the combination
of several features from the conducted analyses allows a
very high confidence in classifying the tissues as normal
or cancerous. The particular combination of pERK1, SRC
peak 6, and p70S6K peak 3 selected here to distinguish
cancer tissue from normal tissue, may or may not indicate
convergence of the included pathways in CRC signaling.
The main objective of the selection was to allow unbiased
diagnosis. Thus, we propose that reliable prognostic and
diagnostic biomarkers should be designed using complex
patterns rather than a single molecular or genetic marker.
For clinical translation, the isoelectric focusing analyses
can easily be made routine and scaled up. For example, 96
unique samples could be run in parallel to yield informa-
tion on three or more selected pathways (by mixing sev-
eral appropriate antibodies yielding non-overlapping
patterns) in a 10 h run in a robotized set-up. Combined
with the powerful computational evaluation to identify
sets of signaling components showing significant charac-
teristics, this strategy could prove to be clinically feasible
for diagnostic purposes beyond the treatment of CRC.
Based on the results obtained this far, we predict that the
measurement of seven protein forms (i.e. selected peaks
from the electropherograms) would be sufficient for the
correct classification of both non-cancerous versus can-
cerous tissue as well as for the CRC grade. Moreover, ana-
lysis of a larger cohort of samples, combined with
information on chosen therapy and disease outcomes,
would allow the use of supervised learning for identifica-
tion of clinically relevant subtypes.
Conclusions
– Highly sensitive robotized isoelectric focusing was
established and a wide range of signal transduction
pathway antibodies were validated. The set-up was
shown to allow detection of signaling status also in
extremely scarce samples, not amenable to
conventional analysis performed in parallel.
– The study revealed dysregulated signal transduction
in several proliferative pathways in human colorectal
cancer tissue, which did not correlate with the
mutation status.
– Computational analysis was used to identify signal
activities consisting of three components that, when
combined, could accurately identify normal mucosa
from cancer.
The study suggests that such combinations of different
signalling activities could serve as predictive or prognos-
tic complex biomarkers.
Additional file
Additional file 1: Figure S1. Validation of antibodies used in the study
by conventional immunoblotting. All antibodies showed
immunoreactivity with the expected molecular species, in conventional
immunoblotting on endothelial lysates. Figure S2. Detection of MEK1/2
protein by isoelectric focusing. There was no significant difference in MEK
protein expression between normal, CRCII and CRCIV tissues. Detailed
description of computational analyses; “Characterization of the data set
and errors”. Figure S3. Distribution function for data subsets by Monte
Carlo simulation. (DOCX 1215 kb)
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